Palvella Therapeutics, Inc.
QTORIN™ rapamycin
Microcystic Lymphatic Malformations
Resolved
7days ago
Catalyst readout · ~ Jun 30, 2026 estimated
What's at stake
A key catalyst for QTORIN™ rapamycin (Microcystic Lymphatic Malformations) is expected ~ Jun 30, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Cutaneous Venous Malformations 2 Positive Phase 2 data BTD application expected to be submitted Q2 2026”